BCWORLD PHARM. Co., Ltd.

As of March 31, 2026, BCWORLD PHARM. Co., Ltd. carries a market capitalization of 46.45B, placing it among publicly traded companies globally. Its enterprise value stands at 131.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, BCWORLD PHARM. Co., Ltd. has 10.22M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.57, and the price-to-book ratio stands at 0.66.

As of March 31, 2026, BCWORLD PHARM. Co., Ltd. trades at an EV/EBITDA multiple of 10.43 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 131.01B versus a market cap of 46.45B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, BCWORLD PHARM. Co., Ltd. maintains a current ratio of 0.56, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.69, indicating elevated leverage, while an interest coverage ratio of 3.05 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, BCWORLD PHARM. Co., Ltd. posted a negative return on equity (ROE) of -3.47, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -2.48, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -1.45, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -5.10, pointing to unprofitable operations over the period. The company generates approximately 280.53M in revenue per employee across its workforce of 284.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.30 indicates how many times BCWORLD PHARM. Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, BCWORLD PHARM. Co., Ltd. recorded 1.03B in income tax expense. That works out to an effective tax rate of 188.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 546.64M, leaving -2.51B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, BCWORLD PHARM. Co., Ltd.'s stock has declined approximately 33.16% over the past 52 weeks. The 50-day moving average sits at 3,029.30, while the 200-day moving average is 4,000.40.

Over the twelve months ended March 31, 2026, BCWORLD PHARM. Co., Ltd. generated 79.81B in revenue and converted that into -2.51B in net income, yielding earnings per share of -48.18. EBITDA reached 12.57B, while operating income came in at 4.50B.

As of March 31, 2026, BCWORLD PHARM. Co., Ltd. holds 4.45B in cash and equivalents against 87.33B in total debt, resulting in a net debt position of 82.91B. Total book value stands at 70.68B, with working capital of -37.76B providing operational flexibility.

BCWORLD PHARM. Co., Ltd. produced 2.17B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -5.25B in capital expenditures, free cash flow totaled -3.08B - equivalent to -308.50 per share.

Over the twelve months ended March 31, 2026, BCWORLD PHARM. Co., Ltd. posted a gross margin of 40.00, reflecting its pricing power and cost economics. The operating margin of 5.64 and net profit margin of -3.14 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, BCWORLD PHARM. Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -6.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BCWORLD PHARM. Co., Ltd. shareholders.

BCWORLD PHARM. Co., Ltd.'s most recent stock split took place on December 29, 2025 with a 10:11 split ratio.

As of March 31, 2026, BCWORLD PHARM. Co., Ltd. has an Altman Z-Score of 0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.